Immediate Impact
3 from Science/Nature 58 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Michael P. Chu being referenced
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
2023
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Michael P. Chu | 547 | 227 | 295 | 237 | 65 | 1.1k | |
| Rajesh Bandekar | 391 | 214 | 255 | 372 | 46 | 1.3k | |
| Yong Wang | 202 | 289 | 428 | 138 | 72 | 1.3k | |
| Sabine Leh | 219 | 89 | 263 | 226 | 84 | 1.3k | |
| Fei Cao | 323 | 100 | 582 | 246 | 74 | 1.3k | |
| Hyunee Yim | 155 | 134 | 257 | 170 | 64 | 1.1k | |
| Olivier Huillard | 527 | 83 | 302 | 422 | 83 | 1.4k | |
| Yoshitsugu Kubota | 308 | 223 | 359 | 206 | 76 | 1.1k | |
| Aart Beeker | 441 | 82 | 334 | 280 | 56 | 1.1k | |
| Harpal S. Dhaliwal | 486 | 184 | 115 | 150 | 35 | 1.3k | |
| Claudio Zanna | 834 | 261 | 403 | 161 | 49 | 1.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...